Cobicistat

BRAND NAMES

• Tybost – the standalone formulation of cobicistat used as a boosting agent 
• Stribild – a fixed-dose combination for HIV treatment 
• Genvoya 
• Prezcobix 
• Evotaz

MECHANISM OF ACTION

Cobicistat acts as a pharmacokinetic enhancer by selectively inhibiting the cytochrome P450 3A (CYP3A) enzyme responsible for metabolizing many antiretroviral drugs. By blocking this enzyme, it increases the plasma concentration and prolongs the action of co-administered drugs such as protease inhibitors and integrase inhibitors. Although it has no direct anti-HIV activity, cobicistat improves the effectiveness and dosing convenience of combination HIV therapies.

PHARMACOKINETICS

Absorption

Cobicistat is well absorbed after oral administration, reaching peak plasma levels within about 3–4 hours. Its absorption is enhanced when taken with food, which improves its bioavailability and ensures effective boosting of co-administered antiretroviral drugs.

Distribution

Cobicistat is highly bound to plasma proteins (about 97–98%), mainly albumin, and has a moderate volume of distribution. This allows it to distribute into body tissues while maintaining stable plasma concentrations for effective boosting of co-administered drugs.

Metabolism

Cobicistat is extensively metabolized in the liver, primarily by the cytochrome P450 3A (CYP3A) enzyme system, with a minor contribution from CYP2D6. It acts as a strong inhibitor of CYP3A, which slows its own metabolism and that of co-administered antiretroviral drugs, enhancing their plasma levels and therapeutic effect.

Elimination

Cobicistat is eliminated mainly through hepatic metabolism, with the majority of the drug excreted in the feces and a smaller portion in the urine. Its elimination half-life is approximately 3–4 hours, allowing it to maintain effective CYP3A inhibition when taken once daily as part of combination antiretroviral therapy.

PHARMACODYNAMICS

Cobicistat has no direct antiviral pharmacodynamic activity against HIV. Instead, its pharmacodynamics are based on potent and selective inhibition of the cytochrome P450 3A (CYP3A) enzyme, along with inhibition of intestinal transport proteins such as P-glycoprotein. By reducing the metabolism and efflux of co-administered antiretroviral drugs, it increases their systemic exposure, prolongs their half-life, and enhances overall therapeutic effectiveness in combination HIV regimens.

ADMINISTRATION

Cobicistat is administered orally, usually as a fixed-dose combination with other antiretroviral agents. It is taken once daily with food to improve absorption and ensure consistent plasma levels. It should be used only as a boosting agent alongside specific drugs such as protease or integrase inhibitors, and not as a standalone HIV treatment.

DOSAGE AND STRENGTH

Cobicistat is commonly available as a 150 mg oral tablet when used as a standalone pharmacokinetic booster. In fixed-dose combinations, it is included at 150 mg alongside other antiretroviral agents, such as elvitegravir, darunavir, or atazanavir. The typical dosing is once daily with food, and the exact strength depends on the combination product being prescribed.

DRUG INTERACTIONS

Cobicistat inhibits CYP3A enzymes, which leads to increased blood levels of many co-administered drugs by slowing their metabolism. This can raise the risk of toxicity with medicines such as certain statins, sedatives, and other antiretrovirals. Drugs that strongly induce CYP3A, like rifampicin or carbamazepine, can reduce its effectiveness. Therefore, careful selection and dose adjustment of interacting medications are required during therapy.

FOOD INTERACTIONS

Cobicistat has no significant food interactions and is usually recommended to be taken with food to improve absorption. Food helps maintain more consistent drug levels, but it does not meaningfully alter its metabolism or effectiveness.

CONTRAINDICATIONS

Cobicistat is contraindicated in patients with hypersensitivity to the drug or its components. It should not be used with medications that are highly dependent on CYP3A metabolism, such as oral midazolam or triazolam, due to risk of serious toxicity. It is also contraindicated with strong CYP3A inducers like rifampicin or St. John’s wort, as these can significantly reduce its effectiveness.

SIDE EFFECTS

• Nausea

• Diarrhea

• Vomiting

• Abdominal pain

• Rash

• Increased serum creatinine (without true kidney damage)

• Elevated liver enzymes

• Jaundice (rare)

OVER DOSE

• No specific antidote available

• Supportive and symptomatic treatment is recommended

• Possible exaggerated CYP3A inhibition leading to increased levels of co-administered drugs

TOXICITY

Cobicistat toxicity is mainly related to excessive CYP3A inhibition, which can increase levels of co-administered drugs and lead to interaction-related adverse effects. It may also cause elevated liver enzymes and a reversible rise in serum creatinine without true kidney damage. Gastrointestinal symptoms like nausea, vomiting, and diarrhea can occur in cases of higher exposure.